Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Patients treated outside NCI centers less likely to receive high-cost lung cancer drugson November 20, 2019 at 1:57 am
... Federal Food and Drug Administration is disallowed to take into account a drug's price when considering approval (unlike its counterpart in Europe, the European Medicines Agency). These factors ...
- Pancreatic Cancer Treatment: New Drug Combination Found Promisingon November 20, 2019 at 1:53 am
The researchers at Stanford Burnham Prebys Medical Discovery Institute have found that a new drug combination of two anti-cancer compounds: MEK inhibitor and L-asparaginase when taken together has ...
- Milestone reached in new leukemia drugon November 19, 2019 at 7:53 pm
The scientists are the first to demonstrate the anti-cancer effect of blocking the Salt-Inducible Kinase 3 (SIK3) pathway in leukemia using YKL-05-099, a drug developed within the lab of Nathanael ...
- A vial of hope: Cancer drug developed at Roswell headed for big clinic trial next yearon November 19, 2019 at 3:57 pm
Traditional treatment for patients involves surgery, radiation and chemotherapy. But in early trials of SurVaxM, when the drug has been added to those other treatments, the survival of patients has ...
- Hepatocellular Carcinoma Drugs Market, by Drug class, Indication and Region | Revolutionary Technology With Size, Share, Growth, Trend, 2018-2026on November 19, 2019 at 5:41 am
This condition can be diagnosed by using ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy combined with ...
- India-Made Anti-Cancer Device Cytotron Gets ‘Breakthrough’ Designation From US FDAon November 19, 2019 at 2:48 am
The anti-cancer device, Cytotron, developed by Bangalore-based Rajah Vijay Kumar received a “breakthrough” designation from the U.S. FDA’s Center for Devices and Radiological Health for the treatment ...
- Researchers identify “mutational footprint” caused by chemotherapy that leads to side effectson November 18, 2019 at 8:02 am
A team of researchers led by Núria López-Bigas, head of the Biomedical Genomics Laboratory at the institute, have identified the specific pattern of DNA mutations caused by six types of widely used ...
- Chemotherapy Drugs Market: Key Facts and Forecast Predictions Presented Until 2023on November 15, 2019 at 2:19 am
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of ...
- Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'on November 15, 2019 at 12:31 am
Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T ...
via Bing News